N–Acetylcysteine and Cisplatin-Induced Nephrotoxicity: Is It a Suitable Antioxidant Supplementation to Prevent Nephrotoxicity in Male or Female Rats?

Document Type : Original Article (s)

Authors

1 MSc Student, Water and Electrolytes Research Center AND Kidney Diseases Research Center AND Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Water and Electrolytes Research Center, AND Department of Physiology, School of Medicine AND Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 Associate Professor, Water and Electrolytes Research Center AND Department of Clinical Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Assistant Professor, Water and Electrolytes Research Center AND Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: N-Acetylcystein (NAC) is a thiol compound with antioxidant effect that can be effective in cancer, cardiovascular disease, HIV infection, and organ toxicity. Cisplatin is widely used in clinics, and the common side effect of this drug is nephrotoxicity that can be also gender related. In order to prevent cisplatin induced nephrotoxicity, antioxidants supplementation is suggested; therefore, the main objective of this study was to determine the preventive role of NAC on cisplatin-induced nephrotoxicity in male and female rats.Methods: 40 Wistar rats of both sexes were studied in six groups. Male rats received a single dose of cisplatin (7 mg/kg) at first day and 600 (group 1) and 300 (group 2) mg/kg/day NAC and saline (group 3) for a period of one week, intraperitoneally. Female rats in the groups 4 to 6 were received similar regimen as the groups 1 to 3, respectively. Before- and after-study serum levels of blood urea nitrogen (BUN), creatinine (Cr), nitric oxide metabolite (nitrite), and magnesium (Mg), and after-study serum levels of superoxide dismutase (SOD) and malondialdehyde (MDA) was measured. The kidney was subjected to pathological investigation to determine the intensity of kidney tissue damage.Findings: No significant difference in the serum levels of MDA, Cr, BUN, nitrite and Mg were observed between the groups not only in male groups but also in female rats. However, the serum level of SOD was significantly different between the groups (P < 0.05). Lack of kidney tissue damage difference between the groups in two different sexes confirmed the ineffectiveness of intraperitoneal administration of NAC to prevent cisplatin-induced nephrotoxicity.Conclusion: The intraperitoneal administration of NAC, as a potent antioxidant, did not protect the kidney against cisplatin-induced nephrotoxicty in male and female rats.

Keywords

References

  1. Fishbane S, Durham JH, Marzo K, Rudnick M. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. J Am SocNephrol 2004; 15(2): 251-60.
  2. Kelly GS. Clinical applications of N-acetylcysteine. Altern Med Rev 1998; 3(2): 114-27.
  3. Planting AS, Catimel G, de Mulder PH, de Graeff A, Höppener F, Verweij J, et al. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Ann Oncol 1999; 10(6): 693-700.
  4. Loehrer PJ Sr, Gonin R, Nichols CR, Weathers T, Einhorn LH. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J ClinOncol 1998; 16(7): 2500-4.
  5. Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18(19): 3390-9.
  6. Bolis G, Favalli G, Danese S, Zanaboni F, Mangili G, Scarabelli C, et al. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer. J ClinOncol 1997; 15(5): 1938-44.
  7. Hoskins P, Eisenhauer E, Vergote I, Dubuc-Lissoir J, Fisher B, Grimshaw R, et al. Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. J ClinOncol 2000; 18(24): 4038-44.
  8. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340(15): 1144-53.
  9. Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J ClinOncol 1996; 14(11): 2901-7.
  10. Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J ClinOncol 2000; 18(22): 3819-28.
  11. Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 2005; 22(5): 441-5.
  12. Boulikas T. Poly(ADP-ribose) synthesis in blocked and damaged cells and its relation to carcinogenesis. Anticancer Res 1992; 12(3): 885-98.
  13. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2010; 2(11): 2490-518.
  14. Wu YJ, Muldoon LL, Neuwelt EA. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J PharmacolExpTher 2005; 312(2): 424-31.
  15. Seguro AC, Poli de Figueiredo LF, Shimizu MH. N-acetylcysteine (NAC) protects against acute kidney injury (AKI) following prolonged pneumoperitoneum in the rat. J Surg Res 2012; 175(2): 312-5.
  16. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006; 354(26): 2773-82.
  17. Appenroth D, Winnefeld K, Schroter H, Rost M. Beneficial effect of acetylcysteine on cisplatin nephrotoxicity in rats. J ApplToxicol 1993; 13(3): 189-92.
  18. Abdelrahman AM, Al Salam S, AlMahruqi AS, Al husseni IS, Mansour MA, Ali BH. N-acetylcysteine improves renal hemodynamics in rats with cisplatin-induced nephrotoxicity. J ApplToxicol 2010; 30(1): 15-21.
  19. Dickey DT, Muldoon LL, Doolittle ND, Peterson DR, Kraemer DF, Neuwelt EA. Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models. Cancer ChemotherPharmacol 2008; 62(2): 235-41.
  20. Silbiger S, Neugarten J. Gender and human chronic renal disease. Gend Med 2008; 5 Suppl A: S3-S10.
  21. Brown WW, Sandberg K. Introduction: gender and kidney disease. Adv Ren Replace Ther 2003; 10(1): 1-2.
  22. Armando I, Jezova M, Juorio AV, Terron JA, Falcon-Neri A, Semino-Mora C, et al. Estrogen upregulates renal angiotensin II AT(2) receptors. Am J Physiol Renal Physiol 2002; 283(5): F934-F943.
  23. Park KM, Kim JI, Ahn Y, Bonventre AJ, Bonventre JV. Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury. J BiolChem 2004; 279(50): 52282-92.
  24. Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis 1995; 25(4): 515-33.
  25. Silbiger SR, Neugarten J. The role of gender in the progression of renal disease.AdvRen Replace Ther 2003; 10(1): 3-14.
  26. Bennett WM, Parker RA, Elliott WC, Gilbert DN, Houghton DC. Sex-related differences in the susceptibility of rats to gentamicin nephrotoxicity. J Infect Dis 1982; 145(3): 370-3.
  27. Nematbakhsh M, Ashrafi F, Safari T, Talebi A, Nasri H, Mortazavi M, et al. Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats. J Nephrol 2012; 25(3): 410-7.
  28. Rafieian-Kopaei M, Nasri H, Nematbakhsh M, Baradaran A, Gheissari A, Rouhi H, et al. Erythropoietin ameliorates gentamicin-induced renal toxicity: A biochemical and histopathological study. J Nephropathology 2012; 1(2): 109-16.
  29. Eshraghi-Jazi F, Nematbakhsh M, Nasri H, Talebi A, Haghighi M, Pezeshki Z, et al. The protective role of endogenous nitric oxide donor (L-arginine) in cisplatin-induced nephrotoxicity: Gender related differences in rat model. J Res Med Sci 2011; 16(11): 1389-96.
  30. Kociba RJ, Sleight SD. Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat. Cancer Chemother Rep 1971; 55(1): 1-8.
  31. Shalansky SJ, Pate GE, Levin A, Webb JG. N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration. Heart 2005; 91(8): 997-9.
  32. Abdin AA, Draz EI, Sarhan NI. Evaluation of the chemoprotective role of N-acetylcysteine on cisplatin-induced nephrotoxicity: new aspect of an old drug. Int J Pharm 2008; 4(5): 339-51.
  33. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22(47): 7265-79.
  34. Zhan Y, van de Water B, Wang Y, Stevens JL. The roles of caspase-3 and bcl-2 in chemically-induced apoptosis but not necrosis of renal epithelial cells. Oncogene 1999; 18(47): 6505-12.
  35. Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z, Cullen KJ. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res 2006; 12(19): 5817-25.
  36. Sprong RC, Winkelhuyzen-Janssen AM, Aarsman CJ, van Oirschot JF, van der Bruggen T, van Asbeck BS. Low-dose N-acetylcysteine protects rats against endotoxin-mediated oxidative stress, but high-dose increases mortality. Am J RespirCrit Care Med 1998; 157(4 Pt 1): 1283-93.
  37. Saleh S, El-Demerdash E. Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic ClinPharmacolToxicol 2005; 97(2): 91-7.
  38. Saad SY, Najjar TA, Daba MH, Al-Rikabi AC. Inhibition of nitric oxide synthase aggravates cisplatin-induced nephrotoxicity: effect of 2-amino-4-methylpyridine. Chemotherapy 2002; 48(6): 309-15.
  39. Nematbakhsh M, Pezeshki Z. Sex-Related difference in nitric oxide metabolites levels after nephroprotectant supplementation administration against cisplatin-induced nephrotoxicity in wistar rat model: the role of vitamin e, erythropoietin, or n-acetylcysteine. ISRN Nephrology 2013; 2013: 1-5.
  40. Banci L, Bertini I, Blazevits O, Calderone V, Cantini F, Mao J, et al. Interaction of cisplatin with human superoxide dismutase. J Am ChemSoc 2012; 134(16): 7009-14.
  41. Nematbakhsh M, Talebi A, Nasri H, Safari T, Dolatkhah S, Ashrafi F, et al. Some evidence for sex-based differences in cisplatininduced nephrotoxicity in rats. Clinical and Experimental Medical Letters 2012; 53(1): 29-32.
  42. Pezeshki Z, Nematbakhsh M, Mazaheri S, Eshraghi-Jazi F, Talebi A, Nasri H, et al. Estrogen Abolishes Protective Effect of Erythropoietin against Cisplatin-Induced Nephrotoxicity in Ovariectomized Rats. ISRN Oncol 2012; 2012: 890310.
Journal of Isfahan Medical School
Volume 31, Issue 229 - Serial Number 229
January and February 2013
Pages 294-304

Files

History

  • Receive Date: 16 January 2013
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics